SATISFYING OUTCOME IN UNPLANNED PREGNANCY DURING BCR-ABL KINASE INHIBITOR (IMATINIB) THERAPY FOR CHRONIC MYELOID LEUKEMIA WITH PHILADELPHIA CHROMOSOME : A CASE REPORT Karnel Singh1, Deviana Soraya Riu2, Dimas Bayu3, Sharvianty Arifuddin4
1Obstetric dan Gynecology Department, Hasanuddin University, Makassar - Indonesia
2Obstetric and Gynecology Department, Fetomaternal Division,
Hasanuddin University, Makassar - Indonesia
3Internal Medicine Department, Hematology Oncology Division,
Hasanuddin University, Makassar - Indonesia
4Obstetric and Gynecology Department, Gynecologic Oncology Division,
Hasanuddin University, Makassar - Indonesia
Abstract
Chronic Myeloid Leukemia (CML) is a myeloproliferative disease characterized by translocation of chromosomes 9 and 22 and oncogenic protein BCR-ABL. There is a woman diagnosed with CML with Philadelphia chromosome who has an unplanned pregnancy during a course of oral chemotherapy treatment with BCR-ABL Kinase Inhibitor (Imatinib) in the first trimester of pregnancy. The pregnancy occurred spontaneously and the patient gave birth at term after induction of labor because the laboratory test results were progressing badly since the discontinuation of oral chemotherapy. A healthy baby boy was born and no congenital defect was found. The use of Imatinib during pregnancy is not of certainty to cause teratogenic effect. However, it is recommended for women receiving oral chemotherapy regiments to use contraceptive method with low failure rate and it is expected that pregnant women who consume Imatinib during pregnancy can be more calm and not panic.
